Sarah Houben

Dr. Sarah Houben


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
AMAlessia Milano
Alessia Milano
AJAlan Juache
Alan Juache
SHSarah Houben
Sarah Houben
MDMaria Grazia Dente
Maria Grazia Dente
CRClaudia Robbiati
Claudia Robbiati
CMCedric Marsboom
Cedric Marsboom
Understanding the risk factors for vector-borne diseases, such as Crimean–Congo hemorrhagic fever (CCHF), is critical for effective public health strategies. This study aims to identify and map the environmental and climatic determinants influencing the distribution of Hyalomma marginatum, the primary vector of CCHF, in Türkiye, using a Multi-Criteria Decision Analysis (MCDA) approach. A rapid literature review was conducted to identify environmental, climatic, and methodological criteria used in MCDA studies on vector-borne diseases. Semi-structured interviews with local experts from Armenia, Serbia, and Türkiye provided fine-scale data on vector presence. These criteria were analyzed using the Analytic Hierarchy Process (AHP) and combined with Weighted Linear Combination (WLC) within the MCDA framework to produce risk maps for H. marginatum occurrence in Türkiye. Key environmental and climatic factors influencing H. marginatum distribution, such as temperature, humidity, vegetation, and precipitation, were identified. The MCDA analysis highlighted high-risk regions in Türkiye with elevated suitability for the vector, correlating with areas of human CCHF cases. MCDA risk maps are valuable tools for public health officials, enabling targeted surveillance and interventions. By integrating diverse environmental and climatic variables, this study enhances the understanding of CCHF dynamics and supports the development of focused control strategies.

3 July 2026 in Vaccine
Verified
Journal Article
Open access
SDStéphanie Depickère
Stéphanie Depickère
PPPieter Pannus
Pieter Pannus
SHSarah Houben
Sarah Houben
ACAlexia Charles
Alexia Charles
LHLeo Heyndrickx
Leo Heyndrickx
MGMaria E. Goossens
Maria E. Goossens
Reduced-dose primo-vaccination against COVID-19 demonstrated safety and immunogenicity, as evidenced by us and others. Fractional booster dosing may similarly maintain strong immunogenicity and protection while reducing reactogenicity, improving acceptability, and conserving supplies. To evaluate the safety and humoral immunogenicity of a reduced-dose (10 μg) versus full-dose (30 μg) BNT162b2 booster in healthy adults. In this single-blind, randomized, non-inferiority follow-up trial in Belgium, 132 adults ≥18 years were enrolled, including participants from the REDU-VAC cohort primed with two doses of either 20 μg or 30 μg BNT162b2. Randomized participants received a 10 μg or 30 μg booster. Blood samples were collected at baseline (D0), day 28 (D28), and month 6 (M6). The primary outcome was SARS-CoV-2 anti-RBD IgG geometric mean titers (GMT) at D28. Secondary outcomes included safety, reactogenicity, anti-RBD IgG titers, neutralizing antibody titers (Wuhan, Omicron BA.1), avidity, and incidence of breakthrough infections (BTI) post D28. Mixed-effects linear models were used to assess the impacts, and a non-inferiority analysis was conducted at D28. No life-threatening adverse events were reported. Reactogenicity was significantly lower in the reduced-dose group (41% vs. 78%, P < 0.0001). Baseline titers were unaffected by priming dose concentration, while previously infected participants exhibited higher titers. At D28, the reduced-dose booster did not meet non-inferiority criteria for humoral immune responses. By M6, antibody titers declined across both groups, with no significant differences between reduced- and full-dose recipients. BTI incidence (69% vs. 62%, P = 0.56) and symptomatology were comparable between groups. The reduced-dose booster elicited moderately lower short-term humoral responses compared to the full dose, but these differences disappeared by six months and had no detectable impact on BTI rates. Combined with a significantly lower reactogenicity profile, reduced-dose regimens represent a cost-effective strategy to sustain immunity and reduce public health burdens. The study was registered at Clinicaltrials.gov (NCT04852861).